← back to search

Adam S. Dingens

Fred Hutch Cancer Center ·
Area of research
Virology · Infectious Diseases
Research interest
Research interests include HIV Research and Treatment, SARS-CoV-2 and COVID-19 Research, Monoclonal and Polyclonal Antibodies Research, and vaccines and immunoinformatics approaches.
h-index
31
citations
9,995
works
71
NIH funding
primary concept
Biology
email

Recent publications

Mapping the neutralizing specificity of human anti-HIV serum by deep mutational scanning
Cell Host & Microbe 2023cited by 30position: middledoi
Dynamics and durability of HIV-1 neutralization are determined by viral replication
Nature Medicine 2023cited by 17position: middledoi
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
Science 2021cited by 856position: middledoi
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
Nature 2021cited by 582position: middledoi
Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016
Cell Reports Medicine 2021cited by 518position: middledoi
Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
Nature Microbiology 2021cited by 327position: middledoi
High-resolution mapping of the neutralizing and binding specificities of polyclonal sera post-HIV Env trimer vaccination
eLife 2021cited by 31position: firstdoi
Functional development of a V3/glycan-specific broadly neutralizing antibody isolated from a case of HIV superinfection
eLife 2021cited by 6position: middledoi
Pseudotyping lentiviral particles with SARS-CoV-2 Spike protein for neutralization assays v2
2021cited by 1position: middledoi
Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding
Cell 2020cited by 2,226position: middledoi
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
Cell Host & Microbe 2020cited by 1,143position: middledoi
Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays
Viruses 2020cited by 888position: middledoi
Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate
Journal of Clinical Microbiology 2020cited by 594position: middledoi
Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection
The Journal of Infectious Diseases 2020cited by 280position: middledoi
Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody
Cell 2020cited by 153position: middledoi
Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak
Nature Communications 2020cited by 75position: firstdoi
dms-view: Interactive visualization tool for deep mutational scanning data
The Journal of Open Source Software 2020cited by 42position: middledoi
APOBEC3C Tandem Domain Proteins Create Super Restriction Factors against HIV-1
mBio 2020cited by 7position: middledoi
Pseudotyping lentiviral particles with SARS-CoV-2 Spike protein for neutralization assays v1
2020cited by 2position: middledoi
Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization
Cell 2019cited by 155position: middledoi
An Antigenic Atlas of HIV-1 Escape from Broadly Neutralizing Antibodies Distinguishes Functional and Structural Epitopes
Immunity 2019cited by 131position: firstdoi
Antibody Lineages with Vaccine-Induced Antigen-Binding Hotspots Develop Broad HIV Neutralization.
PubMed 2019cited by 105position: middledoi
Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features
PLoS Computational Biology 2019cited by 40position: middledoi
Massively Parallel Profiling of HIV-1 Resistance to the Fusion Inhibitor Enfuvirtide
Viruses 2019cited by 19position: firstdoi
HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and are Commonly Detected in Plasma from HIV-infected Humans
EBioMedicine 2015cited by 69position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jesse D. Bloom · Fred Hutch Cancer Center18 papers (2019–2023)Katharine H. D. Crawford · University of Washington9 papers (2020–2023)Julie Overbaugh · Seattle University6 papers (2015–2023)Rachel Eguia · Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa6 papers (2020–2021)Allison J. Greaney · Fred Hutch Cancer Center4 papers (2020–2021)Sarah K. Hilton · St Mary's Hospital4 papers (2020–2021)Andrea N. Loes · Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa4 papers (2020–2021)Tyler N. Starr · University of Utah4 papers (2020–2021)Neil P. King · University of Washington4 papers (2020–2020)Caitlin R. Wolf · University of New Mexico3 papers (2020–2020) · 3 papers (2019–2021)David Veesler · Howard Hughes Medical Institute3 papers (2020–2020)Helen Y. Chu · Seattle Pacific University3 papers (2020–2020)Deleah Pettie · University of Washington3 papers (2020–2020)Alexander L. Greninger · University of Washington2 papers (2020–2020)John Huddleston · Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa2 papers (2020–2020)Florian Klein · Chirurgische Universitätsklinik Heidelberg2 papers (2020–2023) · 2 papers (2019–2021)M. Alejandra Tortorici · University of Washington2 papers (2020–2020)Michael Murphy · University of Washington2 papers (2020–2020)